Liminatus Pharma, a US healthcare company, plans to establish a new company and raise $500 million to invest in BNB

BlockBeats News: On July 28th, according to BusinessInsider, preclinical biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ stock code: LIMN) announced today that it plans to strategically expand into the cryptocurrency and blockchain fields. The company plans to establish a subsidiary called "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to raise and deploy up to $500 million in funding in stages, with the goal of making strategic long-term investments in BNB. Liminatus stressed that although the company is still fully committed to its core business - promoting the development of cancer treatment and pancreatic cancer diagnosis technology, it believes that expanding the field of digital assets is a necessary measure to support long-term growth and enhance shareholder value. Liminatus is a preclinical biopharmaceutical company dedicated to developing immunotherapy for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor specific immune responses.